Core Viewpoint - GSK plc is facing a class action securities lawsuit due to alleged securities fraud related to the withdrawal of Zantac from the market, impacting investors between February 5, 2020, and August 14, 2022 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that GSK misrepresented the reasons for removing Zantac from the market, stating it was based on available information and regulatory correspondence, while in reality, GSK was aware of the source of NDMA for nearly 40 years prior to the withdrawal [2]. - GSK assured investors that there was no evidence linking ranitidine therapy to cancer, which the lawsuit argues was materially false or misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until April 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - GSK plc is facing allegations related to misleading statements about the safety of Zantac, which may have led to investor losses during the specified class period from February 5, 2020, to August 14, 2022 [1] Group 1: Allegations and Legal Context - The complaint alleges that GSK misrepresented the reasons for withdrawing Zantac from the market, claiming it was based on available information and regulatory correspondence, while being aware of the source of NDMA for nearly 40 years [1] - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which the complaint argues was materially false or misleading [1] - The company claimed it could not quantify or reliably estimate its liability, which is also contested in the allegations [1] Group 2: Shareholder Actions and Deadlines - Shareholders who purchased GSK shares during the class period are encouraged to register for the class action, with a deadline of April 7, 2025, to seek lead plaintiff status [2] - Registered shareholders will receive updates through portfolio monitoring software regarding the case's progress [2] Group 3: Law Firm's Mission and Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing the importance of responsible business practices [3] - The firm seeks recovery for investors who suffered losses due to misleading statements that inflated GSK's stock price [3]

Core Viewpoint - A class action securities lawsuit has been filed against GSK plc, alleging securities fraud that affected investors between February 5, 2020, and August 14, 2022 [1]. Group 1: Lawsuit Details - The lawsuit claims that GSK misled investors regarding the removal of Zantac from the market, stating it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years prior to the withdrawal [2]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which was inconsistent with the actual knowledge the company possessed [2]. Group 2: Next Steps for Investors - Investors who suffered losses in GSK during the specified timeframe have until April 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - GSK plc is facing allegations related to misleading statements regarding the withdrawal of Zantac from the market, with claims that the company was aware of the source of NDMA for nearly 40 years before the product's removal [1]. Group 1: Allegations and Legal Context - The class period for the allegations against GSK spans from February 5, 2020, to August 14, 2022 [1]. - Defendants allegedly misrepresented to investors that GSK removed Zantac based on available information and correspondence with regulators, while also claiming that there was no evidence linking ranitidine therapy to cancer [1]. - The complaint asserts that GSK's representations were materially false or misleading, as the company had prior knowledge of the NDMA source [1]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased GSK shares during the specified class period are encouraged to register for the class action, with a deadline set for April 7, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm aims to protect the rights of investors affected by deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock value [3].

Core Viewpoint - A class action securities lawsuit has been filed against GSK plc, alleging securities fraud that affected investors between February 5, 2020, and August 14, 2022 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that GSK misled investors regarding the removal of Zantac from the market, stating it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years prior to the withdrawal [2]. - GSK assured investors that there was no evidence linking ranitidine therapy to cancer, which the lawsuit argues was materially false or misleading [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until April 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].